Chest December 2022 PMID 35952768

Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation.

Nicholas A Bosch, Anica C Law, Emily A Vail, Kari R Gillmeyer, Hayley B Gershengorn, Hannah Wunsch, Allan J Walkey

Mentions

7
Peak: 2 in Aug 2022
across 3 sources since Aug 2022

Extended reach

6,349
potential audience

Total likes

40

Video views

2,234

Mentions per month

Aug 2022 – Aug 2025

Where it's discussed

  • X / Twitter3 posts
  • News3 articles
  • YouTube1 videos

AI synopsis

What people are saying

The discussions reflect a mostly neutral to positive reception, with phrases like 'Radical!' indicating some excitement, while others focus on the practical implications such as hospital preferences. The tone combines curiosity and acknowledgment of the research’s importance, contributing to a nuanced overall assessment.

AgreementModerate agreement

Most posts interpret the study as confirming that there’s no significant difference between the two treatments, showing general agreement with the findings.

InterestModerate interest

Posts reveal a moderate level of interest, mentioning the implications for clinical practice and hospital preferences, indicating engagement beyond basic acknowledgment.

EngagementModerate engagement

Discussions reference specific outcomes like extubation success and hospital costs, suggesting thoughtful participation and analysis.

ImpactModerate impact

The tone and content imply that the study’s results could influence clinical decisions and hospital policies, indicating a moderate level of impact.

Abstract in brief

  • The study compared the effectiveness of inhaled nitric oxide and epoprostenol, two vasodilators used to improve oxygenation in patients with severe acute respiratory failure, finding no significant difference in successful extubation rates, hospital costs, or mortality between the two treatments.
  • Researchers used a large US hospital database to analyze practice patterns and outcomes, focusing on hospitals that exclusively used one of the treatments to reduce bias.
  • The findings highlight significant variation across hospitals in the choice of inhaled vasodilators, but overall, both therapies showed similar effectiveness in managing severe respiratory failure.]

Top posts

Most liked on X and Bluesky
UGAC3
@ugac3 · X

A recent study in the CHEST Journal showed no significant difference in acute respiratory failure outcomes between patients who received nitric oxide versus epoprostenol. Radical! Which agent is preferred at your facility? https://t.co/C7aHJ5l8U3

Feb 15, 2023 · 2 likes · 774 followers View post →
Ayman Soubani, MD
@PagingDrAyman · X

No differences in likelihood of successful extubation between patients in inhaled nitric oxide-only versus inhaled epoprostenol-only hospitals for acute respiratory failure. No differences in total hospital costs or death #MedEd #MedTwitter #PCCMTwitter https://t.co/DLC66LA0vI

Aug 9, 2022 · 1 like · 1 share · 159 followers View post →

All mentions

UGAC3
@ugac3 · X

A recent study in the CHEST Journal showed no significant difference in acute respiratory failure outcomes between patients who received nitric oxide versus epoprostenol. Radical! Which agent is preferred at your facility? https://t.co/C7aHJ5l8U3

Feb 15, 2023 · 2 likes · 774 followers View post →
Meded
@cryptovitas · X

RT @PagingDrAyman: No differences in likelihood of successful extubation between patients in inhaled nitric oxide-only versus inhaled epopr…

Aug 9, 2022 · 1 share · 3,179 followers View post →
Ayman Soubani, MD
@PagingDrAyman · X

No differences in likelihood of successful extubation between patients in inhaled nitric oxide-only versus inhaled epoprostenol-only hospitals for acute respiratory failure. No differences in total hospital costs or death #MedEd #MedTwitter #PCCMTwitter https://t.co/DLC66LA0vI

Aug 9, 2022 · 1 like · 1 share · 159 followers View post →